Sunday, 08 December 2024


SK bioscience invests $3 M in US-based FinaBio specialising in next-gen conjugate vaccine technology

08 October 2024 | News

SK bioscience expects to improve the immunogenicity and productivity of conjugate vaccines

image credit- shutterstock

image credit- shutterstock

South Korea-based SK bioscience has signed an agreement to acquire a stake in Fina Biosolutions, a promising R&D biotechnology company based in Rockville, MarylandUnited States, by investing $3 million. With this acquisition, SK bioscience will become FinaBio's first and sole strategic investor.

FinaBio specialises in the research and development of conjugate vaccines for pneumoniae, meningococcal, typhoid, and other diseases. Among other assets, FinaBio has developed FinaXpress, a proprietary E. coli expression system which they use for producing proteins not previously made in these bacteria, including many carrier proteins like CRM197. Marketed as EcoCRM, FinaBio has expanded access to this critical protein.

FinaBio is also developing a next-generation conjugation technology that is site-specific and targets the desired location for antigen binding, hence boosting immunogenicity and productivity.

SK bioscience, which already manufactures conjugate vaccines such as pneumococcal and typhoid vaccines, will actively utilize FinaBio's CRM197 technology. It aims to secure the high effectiveness of diverse conjugate vaccines while increasing profitability through high-yield processes.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account